What are the main products Amgen was focused on in 1995?

Based on historical knowledge for that period, Amgen's primary commercial products were likely Epogen (epoetin alfa) for anemia associated with chronic renal failure and certain other conditions, and Neupogen (filgrastim) for chemotherapy-induced neutropenia. The 10-K filing would provide sales figures and market performance details for these and potentially other pipeline candidates.

What financial performance indicators should investors look for in this 10-K?

Investors should focus on revenue growth, gross profit margins, operating income, net income, and earnings per share. Trends in these metrics, along with a review of the balance sheet for cash, debt levels, and equity, would be essential. Analyzing the cash flow statement for operating, investing, and financing activities is also critical.

Are there any significant risks mentioned that investors should be aware of?

While the provided text is a directory listing and not the full report, a 10-K typically includes a 'Risk Factors' section. For Amgen in 1995, potential risks would likely include dependence on key products, patent expirations, regulatory approvals and challenges, competition from other biotechnology and pharmaceutical companies, and the success of its research and development pipeline.

Where can I find the full text of the 10-K filing?

The provided text is a directory listing from the SEC's EDGAR system. To access the full 10-K report, you would typically search the SEC EDGAR database using Amgen Inc. (AMGN) and the filing date (March 28, 1996) or the filing type (10-K). Look for the .txt or HTML versions of the document.

AMGN 10-K FY1995 Annual Report — Revenue, Net Income, EPS

Summary

Amgen Inc. (AMGN) filed its 10-K for the fiscal year ending December 30, 1995, on March 28, 1996. While the provided text is primarily a directory listing of the filing's components rather than the full report, it indicates Amgen's adherence to SEC reporting requirements during this period. Investors reviewing this filing would typically look for detailed financial statements, management's discussion and analysis of financial condition and results of operations, and risk factors. Given the 1995 fiscal year, the filing would provide a retrospective view of Amgen's performance and strategic positioning. Key areas of interest for investors would include revenue growth, profitability, key product performance (such as Epogen and Neupogen), research and development pipeline progress, and any significant collaborations or acquisitions. Understanding the company's financial health and future growth prospects as presented in this 10-K would be crucial for investment decisions.

Key Highlights

1The filing represents Amgen Inc.'s 1995 Annual Report (10-K) filed on March 28, 1996.
2The report covers the fiscal year ending December 30, 1995.
3This filing is a historical document providing insights into Amgen's financial performance and operations from that period.
4Investors would typically analyze this report for detailed financial statements, including balance sheets, income statements, and cash flow statements.
5Management's Discussion and Analysis (MD&A) section would offer context on operating results and financial condition.
6Key product performance and the R&D pipeline would be critical components for investor analysis.
7The filing demonstrates Amgen's compliance with SEC reporting regulations as of early 1996.

AMGEN INC Annual Report, Year Ended Dec 31, 1995

Summary

Key Highlights

Frequently Asked Questions